{"id":"W4220742828","doi":"10.1007/s40120-022-00341-z","title":"COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Sanofi Genzyme; Greenwich Biosciences; EMD Serono; National Institutes of Health; Genentech; Multiple Sclerosis Society; International Progressive MS Alliance; Race to Erase MS; TG Therapeutics; Bristol-Myers Squibb; University of Miami; Biogen; Celgene; Alexion Pharmaceuticals; U.S. Department of Defense; Conrad N. Hilton Foundation; Sanofi; National Multiple Sclerosis Society; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries","keywords":"Medicine; Vaccination; Ofatumumab; Coronavirus disease 2019 (COVID-19); Multiple sclerosis; Internal medicine; Pandemic; Pediatrics; Disease; Immunology; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001032247,0.0001722625,0.0003706807,0.0005864772,0.0003988245,0.0005974725,0.000192432,0.0002738034,0.00145004],"category_scores_gemma":[0.002888537,0.0001116614,0.000401305,0.0008736477,0.0002390984,0.0005042715,0.0004626867,0.000430834,0.0001752462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002954012,"about_ca_system_score_gemma":0.0003126739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001683705,"about_ca_topic_score_gemma":0.001919563,"domain_scores_codex":[0.999374,0.0001659396,0.0001062048,0.000106594,0.0001252346,0.0001221824],"domain_scores_gemma":[0.9965466,0.0003189958,0.002579166,0.0000763474,0.0001752486,0.0003037202],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002551382,0.00002009326,0.9971253,0.0000207283,0.0000339592,0.00007360828,0.00007346761,0.00002523576,0.00008304773,0.000009399853,0.0001101792,0.002169794],"study_design_scores_gemma":[0.00001575626,0.0001925289,0.9988425,0.00002324016,0.00002888707,0.0004118563,0.000099758,0.0000672309,0.00006035489,0.0000252176,0.0002298555,0.000002817328],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982073,0.0006832266,0.00003561753,0.00008806677,0.000005856067,0.000007947112,0.0004222163,0.00000375761,0.0005460907],"genre_scores_gemma":[0.9991661,0.0002003779,0.00003602778,0.00003526769,0.00001959486,0.000007053934,0.0004635198,0.000001378265,0.00007062144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001683705,"threshold_uncertainty_score":0.00545913,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05366258251714152,"score_gpt":0.3011824989109759,"score_spread":0.2475199163938344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}